James Sullivan
Chief Tech/Sci/R&D Officer at ENGENE HOLDINGS INC.
James Sullivan active positions
Companies | Position | Start | End |
---|---|---|---|
ENGENE HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 31/10/2023 | - |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 31/01/2022 | - |
Career history of James Sullivan
Former positions of James Sullivan
Companies | Position | Start | End |
---|---|---|---|
TRANSLATE BIO, INC. | Corporate Officer/Principal | 31/12/2020 | 31/01/2022 |
SANA BIOTECHNOLOGY, INC. | Director/Board Member | 31/07/2019 | 31/12/2020 |
Corporate Officer/Principal | 31/07/2019 | 31/12/2020 |
Training of James Sullivan
Boston College | Undergraduate Degree |
University College Dublin | Graduate Degree |
Boston University | Doctorate Degree |
Statistics
International
United States | 4 |
Canada | 3 |
Ireland | 2 |
Operational
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
SANA BIOTECHNOLOGY, INC. | Health Technology |
ENGENE HOLDINGS INC. | Health Technology |
Private companies | 2 |
---|---|
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- James Sullivan
- Experience